Firefly Neuroscience Secures $12.4 Million Funding for Breakthrough Brain Health Technology

Firefly Neuroscience is thrilled to announce a significant funding milestone, securing $12.4 million in a recent financing round. This infusion of capital will further propel our mission to revolutionize neurological assessments through our groundbreaking FDA-cleared Brain Network Analytics (BNA™). At Firefly Neuroscience, we harness the power of advanced artificial intelligence paired with an extensive proprietary database of electroencephalography (EEG) data to provide unparalleled insights into brain health. The BNA™ technology integrates the automatic analysis of Event-Related Potentials (ERPs), spectral EEG, and behavioral performance data, delivering a comprehensive and objective evaluation of neurological function. The newly acquired funding will be allocated towards scaling our innovative platform, enhancing our research and development efforts, and accelerating our go-to-market strategies. With these resources, we aim to expand our research capabilities and deepen our partnerships with healthcare providers to deliver tailored brain health assessments that can lead to more effective treatments for various neurological conditions. As we continue to pioneer new frontiers in brain health technologies, this funding will help us refine our BNA™ system and broaden its applications, ultimately benefiting patients and clinicians alike. We thank our investors for their trust in our vision, and we are excited to lead the charge in making brain health evaluations more precise, informative, and accessible. Together, we are paving the way for a healthier future, one brain at a time.